Clinical Trials Browser

Phase 1 × Lung Neoplasms × Mitogen-Activated Protein Kinase Kinases × Clear all

NCT01859026 2023-01-19

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms